A Nurr1 agonist causes neuroprotection in a parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C)

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Smith, Gaynor A ^a   Rocha, Emily M ^a   Rooney, Thomas ^b   Barneoud, Pascal ^b   McLean, Jesse R ^a   Beagan, Jonathan ^a   Osborn, Teresia ^a   Coimbra, Madeleine ^b   Luo, Yongyi ^c   Hallett, Penelope J ^a   Isacson, Ole ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SANOFI   (France)

^c Drug Metabolism and Pharmacokinetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CELL NUCLEUS RECEPTOR; DOPAMINE; DOPAMINE TRANSPORTER; DOUBLE STRANDED RNA; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 6; MESSENGER RNA; NUCLEAR RECEPTOR RELATED 1; OXIDOPAMINE; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN RET; SA 00025; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER; IMIDAZOLE DERIVATIVE; NUCLEAR RECEPTOR RELATED FACTOR 1; PYRIDINE DERIVATIVE; SA00025; TLR3 PROTEIN, HUMAN;

AADC GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; C RET GENE; CONTROLLED STUDY; DAT GENE; DOPAMINERGIC NERVE CELL; DRUG STRUCTURE; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; IN VIVO STUDY; MALE; NERVE CELL DEGENERATION; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; RAT; TH GENE; TREATMENT OUTCOME; VMAT GENE; AGONISTS; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; INFLAMMATION; METABOLISM; MICROGLIA; NERVE DEGENERATION; PARKINSON DISEASE, SECONDARY; PATHOLOGY; SUBSTANTIA NIGRA PARS COMPACTA;

RATTUS;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; GENE EXPRESSION; IMIDAZOLES; INFLAMMATION; MALE; MICROGLIA; NERVE DEGENERATION; NEUROPROTECTION; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 2; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PARS COMPACTA; POLY I-C; PYRIDINES; RATS; RNA, DOUBLE-STRANDED; TOLL-LIKE RECEPTOR 3;

EID: 84926325705     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121072     Document Type: Article

References (46)

1. Alavian KN, Jeddi S, Naghipour SI, Nabili P, Licznerski P, Tierney TS. The lifelong maintenance of mesencephalic dopaminergic neurons by Nurr1 and engrailed. J Biomed Sci. 2014; 21: 27. doi: 10.1186/1423-0127-21-27 PMID: 24685177
2. Jankovic J, Chen S, Le WD. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol. 2005; 77: 128-138. PMID: 16243425
3. Luo Y. The function and mechanisms of Nurr1 action in midbrain dopaminergic neurons, from development and maintenance to survival. Int Rev Neurobiol. 2012; 102: 1-22. doi: 10.1016/B978-0-12-386986-9.00001-6 PMID: 22748824
4. Sonntag KC, Simantov R, Kim KS, Isacson O. Temporally induced Nurr1 can induce a non-neuronal dopaminergic cell type in embryonic stem cell differentiation. Eur J Neurosci. 2004; 19: 1141-1152. PMID: 15016073
5. Baffi JS, Palkovits M, Castillo SO, Mezey E, Nikodem VM. Differential expression of tyrosine hydroxylase in catecholaminergic neurons of neonatal wild-type and Nurr1-deficient mice. Neuroscience. 1999; 93: 631-642. PMID: 10465447
6. Tan EK, Chung H, Chandran VR, Tan C, Shen H, Yew K, et al. Nurr1 mutational screen in Parkinson's disease. Mov Disord. 2004; 19: 1503-1505. PMID: 15390059
7. Grimes DA, Han F, Panisset M, Racacho L, Xiao F, Zou R, et al. Translated mutation in the Nurr1 gene as a cause for Parkinson's disease. Mov Disord. 2006; 21: 906-909. PMID: 16532445
8. Hering R, Petrovic S, Mietz EM, Holzmann C, Berg D, Bauer P, et al. Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson disease. Neurology. 2004; 62: 1231-1232. PMID: 15079038
9. Tan EK, Chung H, Zhao Y, Shen H, Chandran VR, Tan C, et al. Genetic analysis of Nurr1 haplotypes in Parkinson's disease. Neurosci Lett. 2003; 347: 139-142. PMID: 12875905
10. Chu Y, Kompoliti K, Cochran EJ, Mufson EJ, Kordower JH. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol. 2002; 450: 203-214. PMID: 12209851
11. Moran LB, Croisier E, Duke DC, Kalaitzakis ME, Roncaroli F, Deprez M, et al. Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra. Acta Neuropathol. 2007; 113: 253-263. PMID: 17203291
12. Chu Y, Le W, Kompoliti K, Jankovic J, Mufson EJ, Kordower JH. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006; 494: 495-514. PMID: 16320253
13. Zhang L, Le W, Xie W, Dani JA. Age-related changes in dopamine signaling in Nurr1 deficient mice as a model of Parkinson's disease. Neurobiol Aging. 2012; 33: 1001 e1007-1016.
14. Kadkhodaei B, Alvarsson A, Schintu N, Ramskold D, Volakakis N, Joodmardi E, et al. Transcription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons. Proc Natl Acad Sci U S A. 2013; 110: 2360-2365. doi: 10.1073/pnas.1221077110 PMID: 23341612
15. Zetterstrom RH, Solomin L, Jansson L, Hoffer BJ, Olson L, Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science. 1997; 276: 248-250. PMID: 9092472
16. Decressac M, Kadkhodaei B, Mattsson B, Laguna A, Perlmann T, Bjorklund A. alpha-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med. 2012; 4: 163ra156. doi: 10.1126/scitranslmed.3004676 PMID: 23220632
17. Volpicelli F, Caiazzo M, Greco D, Consales C, Leone L, Perrone-Capano C, et al. Bdnf gene is a downstream target of Nurr1 transcription factor in rat midbrain neurons in vitro. J Neurochem. 2007; 102: 441-453. PMID: 17506860
18. Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG, et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell. 2009; 137: 47-59. doi: 10.1016/j.cell.2009.01.038 PMID: 19345186
19. Deleidi M, Isacson O. Viral and inflammatory triggers of neurodegenerative diseases. Sci Transl Med. 2012; 4: 121ps123. doi: 10.1126/scitranslmed.3003492 PMID: 22344685
20. Deleidi M, Hallett PJ, Koprich JB, Chung CY, Isacson O. The Toll-like receptor-3 agonist polyinosinic: polycytidylic acid triggers nigrostriatal dopaminergic degeneration. J Neurosci. 2010; 30: 16091-16101. doi: 10.1523/JNEUROSCI.2400-10.2010 PMID: 21123556
21. Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation. 2008; 5: 8. doi: 10.1186/1742-2094-5-8 PMID: 18304357
22. Decressac M, Volakakis N, Bjorklund A, Perlmann T. NURR1 in Parkinson disease - from pathogenesis to therapeutic potential. Nat Rev Neurol. 2013; 9: 629-636. doi: 10.1038/nrneurol.2013.209 PMID: 24126627
23. Yi SH, He XB, Rhee YH, Park CH, Takizawa T, Nakashima K, et al. Foxa2 acts as a co-activator potentiating expression of the Nurr1-induced DA phenotype via epigenetic regulation. Development. 2014; 141: 761-772. doi: 10.1242/dev.095802 PMID: 24496614
24. Couch Y, Alvarez-Erviti L, Sibson NR, Wood MJ, Anthony DC. The acute inflammatory response to intranigral alpha-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J Neuroinflammation. 2011; 8: 166. doi: 10.1186/1742-2094-8-166 PMID: 22122884
25. Frank-Cannon TC, Tran T, Ruhn KA, Martinez TN, Hong J, Marvin M, et al. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci. 2008; 28: 10825-10834. doi: 10.1523/JNEUROSCI.3001-08.2008 PMID: 18945890
26. Nguyen TA, Frank-Cannon T, Martinez TN, Ruhn KA, Marvin M, Casey B, et al. Analysis of inflammation-related nigral degeneration and locomotor function in DJ-1(-/-) mice. J Neuroinflammation. 2013; 10: 50. doi: 10.1186/1742-2094-10-50 PMID: 23622116
27. Gao HM, Hong JS, Zhang W, Liu B. Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci. 2003; 23: 1228-1236. PMID: 12598611
28. Mangano EN, Hayley S. Inflammatory priming of the substantia nigra influences the impact of later paraquat exposure: Neuroimmune sensitization of neurodegeneration. Neurobiol Aging. 2009; 30: 1361-1378. doi: 10.1016/j.neurobiolaging.2007.11.020 PMID: 18187236
29. Galleguillos D, Fuentealba JA, Gomez LM, Saver M, Gomez A, Nash K, et al. Nurr1 regulates RET expression in dopamine neurons of adult rat midbrain. J Neurochem. 2010; 114: 1158-1167. doi: 10.1111/j.1471-4159.2010.06841.x PMID: 20533997
30. Wallen AA, Castro DS, Zetterstrom RH, Karlen M, Olson L, Ericson J, et al. Orphan nuclear receptor Nurr1 is essential for Ret expression in midbrain dopamine neurons and in the brain stem. Mol Cell Neurosci. 2001; 18: 649-663. PMID: 11749040
31. Cao JP, Li FZ, Zhu YY, Yuan HH, Yu ZQ, Gao DS. Expressions and possible roles of GDNF receptors in the developing dopaminergic neurons. Brain Res Bull. 2010; 83: 321-330. doi: 10.1016/j.brainresbull.2010.09.009 PMID: 20884338
32. Pratt L, Ni L, Ponzio NM, Jonakait GM. Maternal inflammation promotes fetal microglial activation and increased cholinergic expression in the fetal basal forebrain: role of interleukin-6. Pediatr Res. 2013; 74: 393-401. doi: 10.1038/pr.2013.126 PMID: 23877071
33. Field R, Campion S, Warren C, Murray C, Cunningham C. Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun. 2010; 24: 996-1007. doi: 10.1016/j.bbi.2010.04.004 PMID: 20399848
34. Konat GW, Borysiewicz E, Fil D, James I. Peripheral challenge with double-stranded RNA elicits global up-regulation of cytokine gene expression in the brain. J Neurosci Res. 2009; 87: 1381-1388. doi: 10.1002/jnr.21958 PMID: 19115408
35. Gandhi R, Hayley S, Gibb J, Merali Z, Anisman H. Influence of poly I:C on sickness behaviors, plasma cytokines, corticosterone and central monoamine activity: moderation by social stressors. Brain Behav Immun. 2007; 21: 477-489. PMID: 17267173
36. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009; 8: 382-397. doi: 10.1016/S1474-4422(09)70062-6 PMID: 19296921
37. More SV, Kumar H, Kim IS, Song SY, Choi DK. Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease. Mediators Inflamm. 2013; 2013: 952375. doi: 10.1155/2013/952375 PMID: 23935251
38. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 2003; 106: 518-526. PMID: 14513261
39. Pan J, Zhao YX, Wang ZQ, Jin L, Sun ZK, Chen SD. Expression of FasL and its interaction with Fas are mediated by c-Jun N-terminal kinase (JNK) pathway in 6-OHDA-induced rat model of Parkinson disease. Neurosci Lett. 2007; 428: 82-87. PMID: 17959308
40. Hayley S, Crocker SJ, Smith PD, Shree T, Jackson-Lewis V, Przedborski S, et al. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci. 2004; 24: 2045-2053. PMID: 14985447
41. Woodcock T, Morganti-Kossmann MC. The role of markers of inflammation in traumatic brain injury. Front Neurol. 2013; 4: 18. doi: 10.3389/fneur.2013.00018 PMID: 23459929
42. Helmy AA, Naseer MM, Shafie SE, Nada MA. Role of interleukin 6 and alpha-globulins in differentiating Alzheimer and vascular dementias. Neurodegener Dis. 2012; 9: 81-86. doi: 10.1159/000329568 PMID: 22133543
43. Silvestroni A, Faull RL, Strand AD, Moller T. Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport. 2009; 20: 1098-1103. doi: 10.1097/WNR.0b013e32832e34ee PMID: 19590393
44. Chung CY, Koprich JB, Siddiqi H, Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci. 2009; 29: 3365-3373. doi: 10.1523/JNEUROSCI.5427-08.2009 PMID: 19295143
45. Gillardon F, Schmid R, Draheim H. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience. 2012; 208: 41-48. doi: 10.1016/j.neuroscience.2012.02.001 PMID: 22342962
46. Daher JP, Volpicelli-Daley LA, Blackburn JP, Moehle MS, West AB. Abrogation of alpha-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc Natl Acad Sci U S A. 2014; 111: 9289-9294. doi: 10.1073/pnas.1403215111 PMID: 24927544